financetom
Business
financetom
/
Business
/
Eaton Q2 Adjusted Earnings, Revenue Rise; Updates 2025 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eaton Q2 Adjusted Earnings, Revenue Rise; Updates 2025 Guidance
Aug 5, 2025 4:13 AM

06:55 AM EDT, 08/05/2025 (MT Newswires) -- Eaton (ETN) reported Q2 adjusted earnings Tuesday of $2.95 per diluted share, up from $2.73 a year earlier.

Analysts polled by FactSet expected $2.93.

Revenue for the quarter ended June 30 was $7.03 billion compared with $6.35 billion a year earlier.

Analysts surveyed by FactSet expected $6.91 billion.

For Q3, the company expects adjusted earnings between $3.01 and $3.07 per share on organic growth of 8% to 9%. Analysts surveyed by FactSet expect adjusted earnings of $3.09 per share on revenue of $7.04 billion.

The company narrowed its 2025 adjusted earnings guidance to $11.97 to $12.17 per share from $11.80 to $12.20. It also raised the lower end of its organic growth guidance to 8.5% to 9.5% from organic growth of 7.5% to 9.5%.

Analysts surveyed by FactSet expect adjusted earnings of $12.03 per share on revenue of $27.32 billion.

Shares of the company were down more than 6% in Tuesday's premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
-- EQB Brief: Co Names Marlene Lenarduzzi as interim President and CEO
-- EQB Brief: Co Names Marlene Lenarduzzi as interim President and CEO
Jun 24, 2025
09:53 AM EDT, 06/24/2025 (MT Newswires) -- Price: 94.95, Change: +0.10, Percent Change: +0.11 ...
BioMarin Pharmaceutical Reports Sustained Efficacy for Hemophilia A Gene Therapy in Five-Year Data
BioMarin Pharmaceutical Reports Sustained Efficacy for Hemophilia A Gene Therapy in Five-Year Data
Jun 24, 2025
09:55 AM EDT, 06/24/2025 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) said Tuesday that new five-year data from its Phase 3 study showed roctavian maintained bleed control and factor VIII expression in adults with severe hemophilia A. The trial found 81.3% of participants remained off preventive treatment and 77.8% had no treated bleeds in the fifth year, the company...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
WF Plans Major Investment in China to Expand Operations; Shares Rise
WF Plans Major Investment in China to Expand Operations; Shares Rise
Jun 24, 2025
09:55 AM EDT, 06/24/2025 (MT Newswires) -- WF (WFF) said Tuesday that it plans to make significant investments in China to expand its operations and strengthen international business ties. The manufacturer of fiberglass reinforced plastic products said it is actively scouting corporate land in several regions of China to build new factories. The initiative, which is expected to begin this...
Copyright 2023-2026 - www.financetom.com All Rights Reserved